Sandoz Group AG
π¨πSwitzerland
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 20K
- Market Cap
- $19B
- Website
- http://www.sandoz.com
Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)
Phase 3
Withdrawn
- Conditions
- AnemiaChronic Renal Insufficiency
- Interventions
- Drug: HX575 solution for s.c. administration
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00869856
- Locations
- π§π¬
MHAT "Sveta Anna", Varna, Bulgaria
π§π¬MHAT "Dr. Tota Venkova", Gabrovo, Bulgaria
π«π·Polyclinique de Bordeaux-Nord, Bordeaux, France
Comparative Bioavailability Study of 600mg Azithromycin Monohydrate Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Infection
- Interventions
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 38
- Registration Number
- NCT00866216
To Demonstrate the Relative Bioavailability of Azithromycin 600 mg Tablets Under Fed Conditions
Phase 1
Completed
- Conditions
- Infection
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 38
- Registration Number
- NCT00865670
A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Depression
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 32
- Registration Number
- NCT00864981
Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fed Conditions
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 60
- Registration Number
- NCT00865618
Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 60
- Registration Number
- NCT00865176
A Relative Bioavailability Study of Metformin HCL Tablets, 1000 mg Under Fasting Conditions
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 32
- Registration Number
- NCT00865033
Bioequivalence Study of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 28
- Registration Number
- NCT00864006
To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Depression
- Interventions
- First Posted Date
- 2009-03-16
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 28
- Registration Number
- NCT00861939
A Relative Bioavailability Study of 75mg Indomethacin Extended-Release Capsules
Phase 1
Completed
- Conditions
- Inflammation
- Interventions
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 36
- Registration Number
- NCT00858195
Β© Copyright 2025. All Rights Reserved by MedPath